and Consultant to child care centers and elementary schools with an emphasis on continuous quality improvement and accreditation attainment. Ms. Maguire began volunteering with the Preeclampsia Foundation in January 2006 after experiencing preeclampsia, which resulted in her daughter's premature birth at 29 weeks. She served as the Director of Volunteer Development, National Walk-a-thon chair, and was honored as the 2007 Preeclampsia Foundation Volunteer of the Year. Currently she is a stay-at-home mom and lives with her husband and daughter in Indiana. Ms. Maguire has served on the Preeclampsia Foundation board since 2011.

Matthew Cooper, PhD, DABT

Board Member

Matthew Cooper is currently the CEO and Founder of Carmenta Bioscience, a company developing diagnostic tests for preeclampsia spun out of Stanford School of Medicine in 2012. Matthew's passion for addressing unmet medicalneeds in preeclampsia is a direct result of almost losing his wife during the birth of his son to this horrible syndrome. Matthew has over 15 years experience in biomarker and drug development across all stages of development. He started his career at Biogen Idec and was subsequently recruited to Roche, where he ultimately assumed the role of Global Head of Non-clinical Safety Information. Matthew has also served in leadership roles in miscellaneous industry consortia, including the Chair of the Data Analysis and Management Working Group for the Predictive Safety Testing Consortium (PSTC) at the Critical Path Institute. He recently earned dual MBAs from Columbia Business School and the Berkeley Haas School of Business. He is board certified in toxicology (Diplomat of the American Board of Toxicology) and